Lenses precisely personalized for your face, frame and prescription.
Achieving your best vision possible is more than just an accurate prescription.
It’s also how your prescription lenses are placed in your frames to optimize your viewing range.
Proper lens positioning minimizes headaches, incorrect body posture, and eye strain.
- Better fitting lenses
- Optimum vision
- Reduced eye strain 4
Every face is different. Shouldn't your new glasses be made precisely for yours?
With the help of the ‘Terminal 2, the latest lens-fitting innovation by ZEISS, your eye care professional can provide you with lenses that are precisely personalized for your unique facial features.
Your eye care professional will make sure your chosen frames fit your face.
In only 60 seconds, the i.Terminal 2 takes all of the measurements necessary to accurately fit your new lenses.
As a result of fitting errors, lenses can lose more than 40% of their optical performance. Precision fitting to an accuracy of 0.1mm with the i.Terminal 2 ensures optimum lens performance.
Your new eyeglasses will be made specifically for you, resulting in a faster adaptation and better performing lenses. Seeing is believing! Ask your ZEISS eye care professional for more information about customized lenses and the i.Terminal 2.
Fast. Simple. Precise.
The new standard in centration measurement technology by ZEISS.
ZEISS precision lenses have a long tradition.
For over 160 years, ZEISS has been the world’s leading brand in precision optics. Like NASA, Google Earth, Nobel prize winners, and Hollywood producers, you can enjoy the quality offered by ZEISS, the pioneer in precision optics.
- Google Earth uses ZEISS precision camera lenses to obtain spectacular images of the earth.
- ZEISS microscopes help Nobel prize winners make red blood cells visible.
- ZEISS camera lenses play an important role for directors and camera crews who shoot films like “Lord of the Rings!’
New drugs that work for both adenoviral and bacterial causes of pink eye are needed to relieve symptoms, speed up recovery, and reduce unnecessary antibiotic use when the cause is an adenovirus.
The Synchronize 302 and Synchronize 303 research studies are looking at a non-antibiotic potential new drug targeted for use with two of the most common forms of pink eye - those caused by adenoviruses or bacterial infection.
The non-antibiotic investigational drug is a combination of an antiseptic (which kills certain viruses and bacteria) and a steroid (which aims to reduce pink eye symptoms).
By taking part, you and/or your child may receive a potential new drug for pink eye, and all study-related procedures and visits, including care from an eye specialist, are provided at no cost.
We are looking for about 284 people with pink eye caused by an adenovirus to take part in the Synchronize 302 research study and about 721 people with pink eye caused by bacteria to take part in the Synchronize 303 research study.
Both adults and children of any age may be able to take part in one of the Synchronize research studies. You (or your child) may be able to participate if you (or they):
- have had pink eye signs or symptoms (e.g. redness, watering/discharge, or irritation) in at least one eye for no more than the past 3 days
- are interested in taking part in a research study for up to 13 days
- are willing to travel to the study center for appointments
Additional criteria, including some for newborn infants and young babies, may apply.
Children are often affected by pink eye, and drugs do not always work in the same way for children as they do for adults. It is important that drugs that are intended for use in children have been used by children as part of a research study like this one.
Pink eye infections can be passed between people who have close contact, so it is possible that several people in your household could be affected at the same time. If this happens, all household members who qualify may take part in one of the Synchronize research studies.
The Synchronize 302 and Synchronize 303 research studies will involve five visits to the study center over a 13-day period.
At the first study visit. you will have medical tests to find out if one of the studies is suitable for you. If so. you will be assigned randomly [like rolling dice) to one of three study drug groups. Neither you nor the study team will know which group you are in. You will be asked to use the eye drops four times each day for 7 days.
Group 1 Eye drops containing an antiseptic and a steroid (non-antibiotic investigational drug)
Group 2 Placebo eye drops that contain no active drug
Group 3 (Synchronize 303 study only) Eye drops containing an antiseptic
At the five study visits, a variety of specialist medical tests will be carried out. These will include:
- eye examinations
- vision tests
- eye swabs
- questions about your medical hist any drugs that you are taking
- a urine pregnancy test (if you a who is able to have children)
By taking part in this study, you will find type of pink eye you have (adenoviral or bacterial).
Your participation in this study is entirely volunta You can leave the study at any time, and will need to give a reason. The study team will be e to explain the benefits and risks of taking part in the study. By taking part, you will help to increase our understanding of how pink eye could be treated.
It is important that you contact the study team within 3 days of the start of your symptoms if you are interested in participating. If you are interested in learning more about the Synchronize 302 and Synchronize 303 research studies, please use details provided below to contact the study team.
Eyeland Vision 915-821-6800
4775 Loma del Sur
El Paso, TX 79934
Synchronize 302 and Synchronize 303 Patient information
Do you have redness, watering, or irritation of the eye?
Do you think you might have conjunctivitis, commonly referred to as “pink eye”?
The Synchronize research studies will look at a potential new drug for pink eye caused by adenoviruses or bacteria.
Contact us within 3 days of your symptoms starting to learn whether you could take part in a research study and receive specialist care from the study team.